AnorMED to present at the CIBC World Markets Healthcare Conference

Name	Symbol	Market	Type
iShares Core Moderate Allocation ETF	AMEX:AOM	AMEX	Exchange Traded Fund

	Price Change	% Change	Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.16	0.37%	43.37	43.39	43.2526	43.39	68,947	22:30:49

Moderate Allocation ETF (AMEX:AOM)
Historical Stock Chart

From Jul 2019 to Jul 2024

Click Here for more Moderate Allocation ETF Charts.

VANCOUVER, March 31 /PRNewswire-FirstCall/ -- AnorMED Inc. (AMEX:AOM; TSX:AOM) today announced that the Company will participate at the Annual CIBC World Markets Healthcare Conference in New York City. Michael Abrams, President & CEO, will present at the conference being held at the Millennium Broadway Hotel in New York on Tuesday, April 4 at 3:45pm EST. Live webcasts of the presentation will be available on AnorMED's website at http://www.anormed.com/. About AnorMED Inc. AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. AnorMEDs lead product is MOZOBIL(TM), a first in class stem cell mobilizer, is currently in a Phase III program being conducted in the U.S. for cancer patients undergoing stem cell transplant. The Company plans to complete enrollment in these studies and have 3-month follow-up by the end of 2006. To date over 600 cancer patients have been administered MOZOBIL and safety data has been reported on over 210 subjects. The Company recently reported preliminary activity on AMD070, its lead HIV candidate, currently in a Phase Ib/IIa trial being conducted in the U.S. and U.K. In the area of HIV, AnorMED has also developed a series of compounds that inhibit the CCR5 receptor, and plans to select a lead candidate for clinical studies. AnorMED is currently traded on the American Stock Exchange and the Toronto Stock Exchange under the symbol AOM. Information on AnorMED Inc. is available on the Company's website: http://www.anormed.com/. Note: Certain of the statements contained in this press release may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws, including the Ontario Securities Act, Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. Statements and information regarding strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. The words "anticipates, "believes", "budgets", "could", estimates", expects," forecasts", "intends", "may", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are intended to identify forward-looking statements and information, although not all forward-looking statements and information contain these identifying words. Plans, intentions or expectations disclosed in any forward-looking statements and information should not be read as guarantees of future results or events, and will not necessarily be accurate indications of whether or the times at or by which such results or events will be achieved. Forward-looking statements and information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements and information. Investors are referred to the discussion of such risks, uncertainties and other factors in AnorMED's Final Short Form Prospectus dated December 1, 2005 filed on SEDAR with Canadian securities regulatory authorities and in Exhibit 99.1 to AnorMED's Report on Form 6-K filed with the U.S. Securities and Exchange Commission on December 23, 2005. Except as required by law, AnorMED expressly disclaims any intention and undertakes no obligation to update any forward-looking statements and information as conditions change. For further information: Ms. Elisabeth Whiting, M.Sc. Kim Nelson, Ph.D. VP Corporate Development & Communications Manager, Investor Relations Tel: 604-532-4667 Tel: 604-532-4654 Cell: 604-763-4682 Cell: 604-614-2886 DATASOURCE: AnorMED Inc. CONTACT: Ms. Elisabeth Whiting, M.Sc., VP Corporate Development & Communications, Tel: (604) 532-4667, Cell: (604) 763-4682, E-mail: ; Kim Nelson, Ph.D., Manager, Investor Relations, Tel: (604) 532-4654, Cell: (604) 614-2886, Email:

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

AOM iShares Core Moderate Allocation ETF